◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › I › INVA

Innoviva Inc (INVA) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-15

Innoviva Inc (INVA) operates in the BIOTECHNOLOGY industry and is headquartered in Burlingame, United States with about 159 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, INVA reported $425M in revenue and $271M in net income.

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.

Interactive charts & full statements → Open the INVA valuation workbench →

INVA Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$443M	$425M	$359M	$310M	$331M	$392M	$337M	$261M	$261M	$217M	$134M	$54M	$8M	$5M	$6M	$25M	$24M	$24M	$23M	$22M	$20M
Gross Profit	$324M	$308M	$322M	$268M	$318M	$392M	$0M	$261M	$261M	$217M	$132M	$51M	$1M	($5M)	($3M)	$25M	$24M	$24M	$23M	$22M	$20M
Gross Margin %	73.1%	72.3%	89.8%	86.3%	95.8%	100.0%	0.1%	100.0%	100.0%	100.0%	99.0%	95.2%	11.1%	-99.4%	-45.2%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	$163M	$164M	$167M	$114M	$207M	$375M	$321M	$246M	$238M	$184M	$109M	$32M	($34M)	($29M)	($13M)	($110M)	($78M)	($80M)	($88M)	($169M)	($179M)
Operating Margin %	36.7%	38.5%	46.5%	36.7%	62.5%	95.7%	95.3%	94.4%	91.3%	84.5%	81.6%	58.5%	-402.3%	-635.4%	-231.6%	-447.7%	-323.3%	-329.1%	-380.1%	-766.1%	-914.7%
Net Income	$357M	$271M	$23M	$180M	$214M	$266M	$224M	$157M	$395M	$134M	$60M	($19M)	($168M)	($171M)	($19M)	($115M)	($84M)	($85M)	($94M)	($160M)	($166M)
Net Margin %	80.6%	63.8%	6.5%	57.9%	64.6%	67.8%	66.6%	60.3%	151.4%	61.8%	44.6%	-34.8%	-1997.7%	-3766.6%	-330.3%	-470.6%	-346.2%	-350.0%	-405.4%	-727.2%	-847.7%
EBITDA	$823M	$384M	$85M	$235M	$308M	$361M	$317M	$232M	$237M	$192M	$123M	$46M	($24M)	($150M)	($22M)	($102M)	($71M)	($75M)	($81M)	($165M)	($175M)
Earnings Per Share (EPS)	$4.05	$3.20	$0.32	$2.07	$2.25	$2.82	$1.98	$1.39	$3.48	$1.12	$0.48	$-0.16	$-1.50	$-1.67	$-0.20	$-1.41	$-1.16	$-1.35	$-1.53	$-2.64	$-2.81
Shares Outstanding (M)	73M	85M	74M	87M	95M	94M	114M	113M	113M	120M	123M	115M	112M	102M	91M	82M	72M	63M	61M	60M	59M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INVA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$120M	$98M	$118M	$108M	$100M	$89M	$92M	$90M
Gross Profit	$91M	$76M	$76M	$82M	$90M	$80M	$85M	$80M
Gross Margin %	75.8%	77.4%	64.0%	76.1%	89.4%	90.0%	92.2%	88.8%
Operating Income (EBIT)	$51M	$38M	$39M	$35M	($49M)	($41M)	$43M	$50M
Operating Margin %	42.5%	38.9%	33.0%	32.1%	-48.6%	-46.7%	47.0%	55.6%
Net Income	($83M)	$187M	$164M	$90M	$64M	($47M)	$20M	$1M
Net Margin %	-69.8%	190.4%	139.1%	83.4%	63.5%	-52.6%	22.1%	1.4%
EBITDA	$267M	$239M	$208M	$108M	$84M	($27M)	$36M	$19M
Earnings Per Share (EPS)	$-1.14	$2.20	$1.93	$1.06	$0.75	$-0.74	$0.24	$0.02
Shares Outstanding (M)	73M	85M	85M	85M	84M	63M	84M	63M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INVA Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$191M	$197M	$189M	$141M	$202M	$364M	$313M	$257M	$224M	$142M	$61M	$10M	($131M)	($130M)	($128M)	($88M)	($75M)	($58M)	($100M)	($104M)	($105M)
Capital Expenditures (CapEx)	$3M	$10M	$0M	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$88M	$3M	$4M	$1M	$1M	$1M	$10M	$6M
Free Cash Flow (FCF)	$188M	$186M	$188M	$141M	$202M	$363M	$313M	$257M	$224M	$142M	$61M	$10M	($131M)	($217M)	($131M)	($92M)	($76M)	($59M)	($101M)	($114M)	($110M)
FCF Margin %	42.5%	43.9%	52.5%	45.3%	60.9%	92.5%	93.0%	98.6%	85.6%	65.2%	45.5%	18.8%	-1558.3%	-4795.6%	-2325.7%	-375.2%	-313.8%	-241.3%	-437.0%	-519.0%	-564.1%
Dividends Paid	—	—	—	$96M	—	$0M	$0M	$0M	$0M	$0M	$1M	$87M	$57M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INVA Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$52M	$35M	$55M	$50M	$44M	$49M	$59M	$49M
Capital Expenditures (CapEx)	$0M	$0M	$1M	$1M	$0M	$0M	$4M	$0M
Free Cash Flow (FCF)	$52M	$35M	$53M	$49M	$44M	$49M	$55M	$48M
FCF Margin %	43.1%	35.5%	45.2%	45.1%	44.0%	54.9%	60.2%	54.1%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

INVA Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$1.7B	$1.6B	$1.3B	$1.2B	$1.2B	$926M	$1.0B	$725M	$548M	$367M	$379M	$424M	$522M	$681M	$369M	$259M	$331M	$181M	$236M	$162M	$262M
Cash & Cash Equivalents	$570M	$551M	$305M	$194M	$291M	$202M	$246M	$278M	$62M	$73M	$118M	$159M	$97M	$144M	$95M	$45M	$163M	$48M	$92M	$86M	$72M
Total Liabilities	$469M	$462M	$610M	$569M	$666M	$400M	$392M	$383M	$389M	$610M	$732M	$752M	$745M	$382M	$214M	$346M	$354M	$370M	$371M	$228M	$199M
Total Debt (Short + Long-Term)	$259M	$258M	$450M	$447M	$638M	$395M	$411M	$377M	$383M	$599M	$716M	$739M	$1.5B	$288M	$172M	$173M	$173M	$173M	$173M	$1M	$1M
Total Shareholders' Equity	$1.2B	$1.2B	$691M	$675M	$566M	$415M	$608M	$313M	$154M	($243M)	($353M)	($343M)	($223M)	$299M	$155M	($87M)	($22M)	($189M)	($135M)	($66M)	$63M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INVA viewer.

Other Companies in BIOTECHNOLOGY

ANAB · AnaptysBio Inc — $2 billion
INBX · Inhibrx Biosciences, Inc. — $2 billion
SNDX · Syndax Pharmaceuticals Inc — $2 billion
KARD · Kardigan, Inc. Common Stock — $2 billion
BCAX · Bicara Therapeutics Inc. Common Stock — $1 billion
LTGO · Latigo Biotherapeutics, Inc. Common Stock — $1 billion
RARE · Ultragenyx — $1 billion
AVBP · ArriVent BioPharma, Inc. Common Stock — $1 billion

← INV All “I” companies INVE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.